share_log

HC Wainwright & Co. Initiates Coverage On Candel Therapeutics With Buy Rating, Announces Price Target of $11

HC Wainwright & Co. Initiates Coverage On Candel Therapeutics With Buy Rating, Announces Price Target of $11

HC Wainwright&Co.以買入評級啟動對Candel治療公司的報道,宣佈目標價為11美元
Benzinga Real-time News ·  2022/12/02 06:32

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $11.

HC Wainwright&Co.分析師Vernon Bernardino以買入評級啟動對Candel Treateutics(納斯達克:CADL)的報道,並宣佈目標價為11美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論